Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Clinical trial NCT02311569 · COMPLETED

Trial details

NCT number: NCT02311569
Sponsor: Swiss Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myeloproliferative Neoplasm Primary Myelofibrosis Essential Thrombocythemia Polycythemia Vera

Start date: 2015-04-01
Primary completion: 2016-12-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.